These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12400987)

  • 1. Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinoma.
    Trufflandier N; Gille O; Palussière J; Prié L; Pointillart V; Ravaud A
    Tumori; 2002; 88(4):338-40. PubMed ID: 12400987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
    Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
    Bain C; Merrouche Y; Puisieux I; Blay JY; Negrier S; Bonadona V; Lasset C; Lanier F; Duc A; Gebuhrer L; Philip T; Favrot MC
    Br J Cancer; 1997; 75(2):283-6. PubMed ID: 9010039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
    Diner EK; Linehan M; Walther M
    Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.
    Deshpande H; Dutcher JP; Novik Y; Oleksowicz L
    Cancer J Sci Am; 1999; 5(1):52-3. PubMed ID: 10188062
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic renal cell cancer--is the outlook really improving?
    Waxman J; Thomas H
    Postgrad Med J; 1990 Jun; 66(776):435-40. PubMed ID: 1699216
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 9. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin-2 based therapy for kidney cancer.
    Dutcher JP
    Cancer Treat Res; 2003; 116():155-72. PubMed ID: 14650831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
    Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
    Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldesleukin for metastatic renal cell carcinoma?
    Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study.
    Stoter G; Fosså SD; Rugarli C; Symann M; Jasmin C; Israel L; Bijman JT; Palmer P; Franks CR; Philip T
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():111-3. PubMed ID: 2670207
    [No Abstract]   [Full Text] [Related]  

  • 14. Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma.
    Medeiros BC; Kogel KE; Kane MA
    Transfus Apher Sci; 2003 Aug; 29(1):25-7. PubMed ID: 12877889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma.
    Oleksowicz L; Escott P; Leichman GC; Spangenthal E
    Am J Clin Oncol; 2000 Feb; 23(1):34-6. PubMed ID: 10683072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome].
    Brinkmann OA; Roigas J; Hertle L
    Urologe A; 2002 May; 41(3):231-8. PubMed ID: 12132272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
    Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
    Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2.
    Sparano JA; Brandt LJ; Dutcher JP; DuBois JS; Atkins MB
    Ann Intern Med; 1993 Apr; 118(8):617-8. PubMed ID: 8452327
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.
    Jensen HK; Donskov F; Nordsmark M; Marcussen N; von der Maase H
    Clin Cancer Res; 2009 Feb; 15(3):1052-8. PubMed ID: 19188179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.